UBS reiterates its "buy" rating on SIMCERE PHARMA (02096) with a target price of HK$16.30.

UBS reiterated its "buy" rating on Simcere Pharma (02096) in a research report released on Monday, with a target price of HK$16.30. At the same time, Wall Street analysts generally gave Simcere Pharma a "strong buy" rating, with an average target price of HK$17.77. According to Simcere Pharma's latest quarterly performance as of December 31, 2025, the company achieved revenue of HK$4.15 billion and a net profit of HK$740.4 million in the quarter. In comparison, in the same period last year, the company achieved revenue of HK$3.52 billion and a net profit of HK$276.57 million.